RU2764724C2 - Комбинированная терапия для лечения рака молочной железы - Google Patents

Комбинированная терапия для лечения рака молочной железы Download PDF

Info

Publication number
RU2764724C2
RU2764724C2 RU2019132893A RU2019132893A RU2764724C2 RU 2764724 C2 RU2764724 C2 RU 2764724C2 RU 2019132893 A RU2019132893 A RU 2019132893A RU 2019132893 A RU2019132893 A RU 2019132893A RU 2764724 C2 RU2764724 C2 RU 2764724C2
Authority
RU
Russia
Prior art keywords
inhibitor
pharmaceutically acceptable
acceptable salt
erα
administered
Prior art date
Application number
RU2019132893A
Other languages
English (en)
Russian (ru)
Other versions
RU2019132893A (ru
RU2019132893A3 (enExample
Inventor
Крейг Д. КАРР
Манав КОРПАЛ
Натали РИУ
Петер Герард СМИТ
Original Assignee
ЭИСАЙ Р энд Д МЕНЕДЖМЕНТ КО., ЛТД.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ЭИСАЙ Р энд Д МЕНЕДЖМЕНТ КО., ЛТД. filed Critical ЭИСАЙ Р энд Д МЕНЕДЖМЕНТ КО., ЛТД.
Publication of RU2019132893A publication Critical patent/RU2019132893A/ru
Publication of RU2019132893A3 publication Critical patent/RU2019132893A3/ru
Application granted granted Critical
Publication of RU2764724C2 publication Critical patent/RU2764724C2/ru

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/453—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
RU2019132893A 2017-03-16 2018-03-16 Комбинированная терапия для лечения рака молочной железы RU2764724C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762472345P 2017-03-16 2017-03-16
US62/472,345 2017-03-16
PCT/US2018/022961 WO2018170447A1 (en) 2017-03-16 2018-03-16 Combination therapies for the treatment of breast cancer

Publications (3)

Publication Number Publication Date
RU2019132893A RU2019132893A (ru) 2021-04-16
RU2019132893A3 RU2019132893A3 (enExample) 2021-06-24
RU2764724C2 true RU2764724C2 (ru) 2022-01-19

Family

ID=61874039

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2019132893A RU2764724C2 (ru) 2017-03-16 2018-03-16 Комбинированная терапия для лечения рака молочной железы

Country Status (14)

Country Link
US (1) US11083722B2 (enExample)
EP (2) EP4218820A3 (enExample)
JP (1) JP7219224B2 (enExample)
KR (1) KR102517650B1 (enExample)
CN (1) CN110636862B (enExample)
AU (1) AU2018234903B2 (enExample)
BR (1) BR112019019261A2 (enExample)
CA (1) CA3056701A1 (enExample)
IL (1) IL269357B2 (enExample)
MA (1) MA47776A (enExample)
MX (1) MX2019010981A (enExample)
RU (1) RU2764724C2 (enExample)
SG (1) SG11201908531WA (enExample)
WO (1) WO2018170447A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109790141B (zh) * 2016-11-28 2021-06-11 卫材 R&D 管理有限公司 吲唑衍生物的盐及其晶体
WO2019136451A1 (en) 2018-01-08 2019-07-11 G1 Therapeutics, Inc. G1t38 superior dosage regimes
EP4240357A1 (en) * 2020-11-06 2023-09-13 Eisai R&D Management Co., Ltd. Method of treating breast cancer
CN113018357A (zh) * 2021-02-08 2021-06-25 湖南农业大学 茶多酚和帕博西尼联合在制备治疗乳腺癌的制剂中的用途
EP4626890A1 (en) 2022-12-01 2025-10-08 KRKA, d.d., Novo mesto Ribociclib salts and formulations thereof

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2421224C2 (ru) * 2006-04-21 2011-06-20 Гем Фармасьютикалс, Ллс Лечение раковых заболеваний при помощи комбинации таксанов и 13-дезоксиантрациклинов
GB2483736A (en) * 2010-09-16 2012-03-21 Aragon Pharmaceuticals Inc Estrogen receptor modulators and use thereof
WO2015022609A1 (en) * 2013-08-14 2015-02-19 Novartis Ag Combination therapy for the treatment of cancer
US20160347717A1 (en) * 2015-05-29 2016-12-01 Eisai R&D Management Co., Ltd. Tetrasubstituted alkene compounds and their use
RU2015125307A (ru) * 2012-11-28 2017-01-10 Новартис Аг Комбинированная терапия

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6399633B1 (en) 1999-02-01 2002-06-04 Aventis Pharmaceuticals Inc. Use of 4-H-1-benzopryan-4-one derivatives as inhibitors of smooth muscle cell proliferation
DE19959546A1 (de) 1999-12-09 2001-06-21 Rhone Poulenc Rorer Gmbh Pharmazeutische Zubereitung zur Behandlung von Tumorerkrankungen
TR200402036T4 (tr) 2000-01-18 2004-10-21 Aventis Pharmaceuticals Inc. (-)-Cis-2-(2-Klorofenil)-5, 7-Dihidroksi-8-[4R-(3S-Hidroksi-1-Metil) Piperidinil]-4H-1- Benzopiran-4-on'un psödopolimorfu
IL150643A0 (en) 2000-01-18 2003-02-12 Aventis Pharma Inc Ethanol solvate of (-)-cis-2-(2-chlorophenyl)-5,7-dihydroxy-8 [4r-(3s-hydroxy-1-methyl) piperidinyl]-4h-1-benzopyran-4-one
WO2002022133A1 (en) 2000-09-12 2002-03-21 Virginia Commonwealth University Promotion of adoptosis in cancer cells by co-administration of cyclin dependent kinase inhibitors and cellular differentiation agents
NZ534069A (en) 2002-01-22 2007-03-30 Warner Lambert Co 2-(Pyridin-2-ylamino)-pyrido[2,3-d]pyrimidin-7-ones to be used to treat neurodegenerative disorders, viruses and cancer
EP2256106B1 (en) 2003-07-22 2015-05-06 Astex Therapeutics Limited 3,4-disubstituted 1H-pyrazole compounds and their use as cyclin dependent kinases (CDK) and glycogen synthase kinase-3 (GSK-3) modulators
EP1845974A1 (en) 2005-01-21 2007-10-24 Astex Therapeutics Limited Pharmaceutical compounds
EP1845973B1 (en) 2005-01-21 2015-08-12 Astex Therapeutics Limited Pharmaceutical compounds
AR054425A1 (es) 2005-01-21 2007-06-27 Astex Therapeutics Ltd Sales de adicion de piperidin 4-il- amida de acido 4-(2,6-dicloro-benzoilamino) 1h-pirazol-3-carboxilico.
WO2006077425A1 (en) 2005-01-21 2006-07-27 Astex Therapeutics Limited Combinations of pyrazole kinase inhibitors and further antitumor agents
JP2008255008A (ja) 2005-07-19 2008-10-23 Tokyo Medical & Dental Univ 滑膜細胞増殖抑制剤
TWI398252B (zh) 2006-05-26 2013-06-11 諾華公司 吡咯并嘧啶化合物及其用途
JP2009542608A (ja) 2006-06-29 2009-12-03 アステックス・セラピューティクス・リミテッド 医薬組合せ剤
EP2049106A2 (en) 2006-07-14 2009-04-22 Astex Therapeutics Limited Pharmaceutical combinations
JP2009543770A (ja) 2006-07-14 2009-12-10 アステックス・セラピューティクス・リミテッド Ｃｄｋ及びｇｓｋの阻害のためのピラゾール誘導体の組合せ剤
EP2046327A1 (en) 2006-07-21 2009-04-15 Astex Therapeutics Limited Medical use of cyclin dependent kinases inhibitors
US7902147B2 (en) 2007-11-05 2011-03-08 Duke University Chronic lymphocytic leukemia prognosis and treatment
AU2009284098B2 (en) 2008-08-22 2012-03-29 Astex Therapeutics Ltd. Pyrrolopyrimidine compounds as CDK inhibitors
PA8852901A1 (es) 2008-12-22 2010-07-27 Lilly Co Eli Inhibidores de proteina cinasa
UY33226A (es) 2010-02-19 2011-09-30 Novartis Ag Compuestos de pirrolopirimidina deuterada como inhibidores de la cdk4/6
US20130035336A1 (en) 2010-04-13 2013-02-07 Novartis Ag Combination comprising a cyclin dependent kinase 4 or cyclin dependent kinase (cdk4/6) inhibitor for treating cancer
KR102186969B1 (ko) 2010-10-25 2020-12-04 쥐원 쎄라퓨틱스, 인크. Cdk 억제제
AR083797A1 (es) 2010-11-10 2013-03-20 Novartis Ag Succinato de dimetil-amida del acido 7-ciclopentil-2-(5-piperazin-1-il-piridin-2-il-amino)-7h-pirrolo-[2,3-d]pirimidin-6-carboxilico, proceso para prepararla, intermediarios de dicha sintesis y proceso de preparacion de los mismos
KR101606250B1 (ko) 2011-03-23 2016-03-24 암젠 인크 Cdk 4/6 및 flt3의 융합된 트리사이클릭 이중 저해제
JP6430483B2 (ja) 2013-03-15 2018-11-28 ジー１、セラピューティクス、インコーポレイテッドＧ１ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． 化学療法の間の正常細胞の一時的な保護
SG11201607334YA (en) 2014-03-13 2016-10-28 Hoffmann La Roche Therapeutic combinations with estrogen receptor modulators
WO2016025650A1 (en) 2014-08-13 2016-02-18 Celgene Avilomics Research, Inc. Combinations of an erk inhibitor and a cdk4/6 inhibitor and related methods
WO2016040848A1 (en) 2014-09-12 2016-03-17 G1 Therapeutics, Inc. Treatment of rb-negative tumors using topoisomerase inhibitors in combination with cyclin dependent kinase 4/6 inhibitors
CN104529904B (zh) 2015-01-09 2016-08-31 苏州明锐医药科技有限公司 玻玛西尼的制备方法
US20160220569A1 (en) 2015-02-03 2016-08-04 G1 Therapeutics, Inc. CDK4/6 Inhibitor Dosage Formulations For The Protection Of Hematopoietic Stem And Progenitor Cells During Chemotherapy
MX384605B (es) * 2015-04-29 2025-03-14 Radius Pharmaceuticals Inc Combinación de palbociclib y rad1901 para usarse en el tratamiento de cáncer de mama en un sujeto con cáncer positivo a receptor de estrógeno.

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2421224C2 (ru) * 2006-04-21 2011-06-20 Гем Фармасьютикалс, Ллс Лечение раковых заболеваний при помощи комбинации таксанов и 13-дезоксиантрациклинов
GB2483736A (en) * 2010-09-16 2012-03-21 Aragon Pharmaceuticals Inc Estrogen receptor modulators and use thereof
RU2015125307A (ru) * 2012-11-28 2017-01-10 Новартис Аг Комбинированная терапия
WO2015022609A1 (en) * 2013-08-14 2015-02-19 Novartis Ag Combination therapy for the treatment of cancer
US20160347717A1 (en) * 2015-05-29 2016-12-01 Eisai R&D Management Co., Ltd. Tetrasubstituted alkene compounds and their use

Also Published As

Publication number Publication date
SG11201908531WA (en) 2019-10-30
AU2018234903A1 (en) 2019-10-10
IL269357B1 (en) 2024-06-01
EP4218820A3 (en) 2023-09-20
RU2019132893A (ru) 2021-04-16
US20210113537A1 (en) 2021-04-22
CN110636862B (zh) 2026-03-20
EP3595725B1 (en) 2023-05-03
WO2018170447A1 (en) 2018-09-20
CA3056701A1 (en) 2018-09-20
IL269357A (en) 2019-11-28
EP4218820A2 (en) 2023-08-02
JP7219224B2 (ja) 2023-02-07
MA47776A (fr) 2020-01-22
US11083722B2 (en) 2021-08-10
KR20190125448A (ko) 2019-11-06
KR102517650B1 (ko) 2023-04-05
RU2019132893A3 (enExample) 2021-06-24
IL269357B2 (en) 2024-10-01
EP3595725A1 (en) 2020-01-22
MX2019010981A (es) 2020-09-07
AU2018234903B2 (en) 2024-02-08
CN110636862A (zh) 2019-12-31
BR112019019261A2 (pt) 2020-06-16
JP2020510075A (ja) 2020-04-02

Similar Documents

Publication Publication Date Title
CN108024541B (zh) 用于治疗癌症的方法
US11083722B2 (en) Combination therapies for the treatment of breast cancer
CN109803684B (zh) 用于治疗肝细胞癌的组合疗法
US20240173293A1 (en) Treatment of Breast Cancer with Amcenestrant and Palbociclib
CA3123510A1 (en) Combination therapy with a raf inhibitor and a cdk4/6 inhibitor for use in the treatment of cancer
JP2023175825A (ja) 肝細胞癌の治療のための併用療法
WO2022043955A1 (en) Combination therapy of a raf inhibitor and a mek inhibitor for the treatment of sarcoma
JP7372740B2 (ja) 細胞生存性及び／又は細胞増殖を低減するための薬物の組み合わせ
CN112004525A (zh) 注射用组合物
RU2787993C2 (ru) Комбинированные терапии для лечения гепатоцеллюлярной карциномы
TW202416992A (zh) 雌激素受體降解劑之給藥方案
US20030139430A1 (en) Use of organic compounds
BR112021010141A2 (pt) Métodos para o tratamento de câncer em modelos protegendo mutações esri
KR20220012891A (ko) 에스트로겐 수용체-알파 억제제의 경구 투여 형태로 암을 치료하는 방법
RU2820478C2 (ru) Способы лечения устойчивого к ингибиторам cdk4/6 рака